ASH Conference Coverage
Featured News
(Reuters) Dec 9, 2019 - Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in patients who did not respond to prior treatments. The lowest dose of the therapy, bb21217, had a median duration of response of...
(ASH) Dec 10, 2019 - The immunotherapy drug blinatumomab significantly improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy in a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. Researchers say the...
(Morningstar/Dow Jones) Dec 10, 2019 - Bristol-Myers Squibb Co. presented survival and safety data from its study evaluating CC-486 as maintenance therapy in a broad population of patients with front-line, newly diagnosed acute myeloid leukemia. In the QUAZAR AML-001 study, treatment with CC-486 in the maintenance setting provided...
(MarketWatch) Dec 10, 2019 - Amgen Inc. on Tuesday said a phase 3 study evaluating Kyprolis in combination with dexamethasone and Darzalex met its primary endpoint in patients with the blood cancer multiple myeloma. The Thousand Oaks, Calif., biotechnology company said the study met its main endpoint of progression-free survival,...
(Xconomy New York) Dec 9, 2019 - Merck is acquiring cancer drug developer ArQule for $2.7 billion, a cash deal that brings it a promising early-stage compound that could challenge a blockbuster leukemia drug from AbbVie. According to terms of the agreement announced Monday, a Merck subsidiary will pay $20 for each share of ArQule, a...
(BMS) Dec 8, 2019 - Heavily pre-treated patients with chronic lymphocytic leukemia receiving liso-cel achieved durable complete responses, including undetectable minimal residual disease. Preliminary data from the PILOT study showed promising efficacy and safety as second-line therapy in patients with aggressive relapsed or refractory...
(ArQule) Dec 9, 2019 - ArQule, Inc. today announced final results from the phase 1 study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK) in patients with relapsed or refractory hematologic malignancies at ASH 2019 in Orlando, Florida. “The...
(AJMC Managed Markets Network) Dec 7, 2019 - Successors to the first generation of chimeric antigen receptor (CAR) T-cell treatments will attack multiple targets and address the complexity of the manufacturing process by bringing uniformity to the creation of therapies, presenters said at the 61st American Society of Hematology Annual...
(Regeneron) Dec 8, 2019 - Regeneron Pharmaceuticals, Inc. today announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory (R/R) multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. REGN5458 is designed to...
(Lilly) Dec 8, 2019 - Responses observed at all dose levels in Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL), including patients with BTK Resistance, BTK Intolerance, and BCL2 Resistance. Eli Lilly and Company today announced interim clinical data from the LOXO-305 global Phase 1/2 BRUIN dose escalation trial....
(Fate) Dec 8, 2019 - Fate Therapeutics, Inc. announced new in vivo preclinical data for FT596, its off-the-shelf, multi-antigen targeting natural killer (NK) cell product candidate derived from a clonal master engineered induced pluripotent stem cell (iPSC) line. The data were featured during the 61stAmerican Society of Hematology...
(Janssen) Dec 7, 2019 - The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T)...
(Reuters) Dec 7, 2019 - Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial. The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year.
(Reuters) Dec 7, 2019 - Nearly half of lymphoma patients treated with Gilead Sciences Inc’s Yescarta were alive at least three years after a one-time infusion of the CAR-T cell therapy, according to data presented on Saturday. Out of 101 patients teated with Yescarta for an aggressive blood cancer known as refractory large B-cell...
(Sunesis) Dec 5, 2019 - Sunesis Pharmaceuticals, Inc. today announced data from the Company’s Phase 1b/2 clinical trial of its non-covalent BTK inhibitor vecabrutinib in adults with relapsed/refractory chronic lymphocytic leukemia (CLL) and other B-cell malignancies. The results will be presented on Sunday, December 8, from...
(AP) Dec 2, 2019 - Epizyme Inc. today announced that the Oncologic Drugs Advisory Committee (ODAC) of the U.S. Food and Drug Administration (FDA) is scheduled to review data supporting the company’s New Drug Application (NDA) requesting accelerated approval for tazemetostat, an oral, first-in-class EZH2 inhibitor, at a meeting on Dec....
(Sanofi) Nov 21, 2019 - Sutimlimab, an investigational targeted C1s inhibitor, met its primary efficacy endpoint in Phase 3 trial for patients with cold agglutinin disease (CAD). CAD is a severe and chronic rare blood disorder in which the immune system mistakenly attacks a person's own healthy red blood cells. There are currently no...
(STAT Plus) Nov 6, 2019 - Important new data on closely followed blood cancer treatments — including personalized CAR-T therapies from Celgene, Bluebird Bio, and Johnson & Johnson — emerged Wednesday in research abstracts released by the American Society of Hematology (ASH). The abstracts offer preliminary looks at clinical...
View all
More News
(Yahoo! Finance) Dec 12, 2019 - Lead investigators from US and French Phase Ib/II clinical trials of APR-246 and Azacitidine (AZA) in patients with TP53 mutant MDS and AML, presented positive data on Monday at the 2019 ASH Annual Meeting. Both trials are evaluating the safety and efficacy of Aprea Therapeutics, Inc. lead product...
(NCI) Dec 10, 209 - New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed. Those treated with blinatumomab had longer survival,...
(ASH) Dec 10, 2019 - Using an investigational oral form of azacitidine therapy, CC-486, significantly improved overall survival in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy with or without consolidation therapy, according to a phase III study presented...
(ASH) Dec 10, 2019 - The immunotherapy drug blinatumomab significantly improved survival in children with relapsed B-acute lymphoblastic leukemia (B-ALL) compared with standard chemotherapy in a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. Researchers say the...
(Morningstar/Dow Jones) Dec 10, 2019 - Bristol-Myers Squibb Co. presented survival and safety data from its study evaluating CC-486 as maintenance therapy in a broad population of patients with front-line, newly diagnosed acute myeloid leukemia. In the QUAZAR AML-001 study, treatment with CC-486 in the maintenance setting provided...
(ASH) Dec 10, 2019 - Adding daratumumab to carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma led to a significant survival benefit, according to a study presented today during the 61st American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando. Researchers say the results...
(ASH) Dec 10, 2019 - Researchers have completed the first comprehensive analysis combining full genomic sequencing and gene expression profiles of more than 1,300 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). AML and MDS are blood cancers that undermine the body’s ability to make healthy blood cells....
(MarketWatch) Dec 10, 2019 - Amgen Inc. on Tuesday said a phase 3 study evaluating Kyprolis in combination with dexamethasone and Darzalex met its primary endpoint in patients with the blood cancer multiple myeloma. The Thousand Oaks, Calif., biotechnology company said the study met its main endpoint of progression-free survival,...
(bluebird bio) Dec 9, 2019 - More than four years of durable transfusion independence (TI), stable total hemoglobin (Hb) levels and reduced liver iron concentrations in completed Phase 1/2 Northstar (HGB-204) study in patients who do not have a β0/β0 genotype.
(BMS) Dec 9, 2019 - Bristol-Myers Squibb Company and Acceleron Pharma today announced data evaluating the erythroid maturation agent (EMA) Reblozyl ® (luspatercept-aamt) in patients with anemia associated with a range of serious and rare blood diseases were presented at the 2019 ASH Annual Meeting in Orlando, Fla.
(Chimerix) Dec 10, 2019 - Chimerix, Inc. today announced that data relating to its dociparstat sodium (DSTAT) program, formerly known as CX-01, were presented at the 61st American Society of Hematology Annual Meeting, in Orlando, FL.
(Celyad) Dec 10, 2019 - Celyad today announced updates to the company’s autologous NKG2D-based CAR-T development program for the treatment of relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) at ASH.
(Stemline) Dec 10, 2019 - Stemline Therapeutics, Inc. presented data from ELZONRIS® (tagraxofusp) Phase 1/2 clinical trials in myelofibrosis (oral presentation) and multiple myeloma, at the 2019 ASH annual meeting.
(Fate Therapeutics) Dec 10, 2019 - Fate Therapeutics announced new in vivo preclinical data for FT819, its first off-the-shelf, iPSC-derived chimeric antigen receptor (CAR) T-cell product candidate, at the 61st American Society of Hematology (ASH) Meeting and Exposition in Orlando, Florida.
Featured Videos
There are no featured ASH Conference Coverage videos.

OBR Tweets

Jul 09
H. Jack West, MD: The benefit of low dose chest CT screening for lung cancer remains somewhat controversial, but th… https://t.co/8wOgsSCY7q

Jul 08
Howard S. Hochster, MD: While a "complete response" is great for our patients, the Complete Response Letter was les… https://t.co/yQGkfvpMCF

Jul 02
A panel of three breast cancer experts looked at some of the big studies at #ASCO20 and discussed treatment advance… https://t.co/ve0XD0cWDY

Jul 01
A report on several promising studies at #ASCO20 focused on personalized therapies for patients with unmet needs. I… https://t.co/lc4BoQ3Evl

Jul 01
At #ASCO’s virtual meeting, studies featured potentially practice-changing data. Among the studies were the BOSTON… https://t.co/6pXpxFomwu

Jun 22
Howard S. Hochster, MD: Another, but far more problematic approval for Pembro. Which tumors actually have high TMB… https://t.co/pBSquns9mN

Jun 19
Dean Gesme, MD: The positive primary endpoint of improved iDFS with Abemaciclib plus adjuvant AI in this Monarch E… https://t.co/GXnYhO8jov

Jun 17
Thomas Marsland, MD: I actually enjoyed the experience. I certainly missed mingling with friends and colleagues. Al… https://t.co/gVtYjkzPzy

Jun 16
Derek Raghavan, MD, on @LevineCancer provides a general overview of prostate cancer therapies #ASCO20 https://t.co/niwz0yPHjB

Jun 16
H. Jack West, MD: We await phase 3 data, but many will welcome a new option with an approximately 35% response rate… https://t.co/Ld5N8KrWye